138 related articles for article (PubMed ID: 38676794)
1. Patient-Derived Xenograft Models for Leukemias.
Brown FC; Carmichael CL
Methods Mol Biol; 2024; 2806():31-40. PubMed ID: 38676794
[TBL] [Abstract][Full Text] [Related]
2. An Improved Protocol for Establishment of AML Patient-Derived Xenograft Models.
Hassan N; Yang J; Wang JY
STAR Protoc; 2020 Dec; 1(3):100156. PubMed ID: 33377050
[TBL] [Abstract][Full Text] [Related]
3. [Knowledge and practice of patient-derived xenograft models in leukemia].
Kato I
Rinsho Ketsueki; 2022; 63(9):1335-1343. PubMed ID: 36198560
[TBL] [Abstract][Full Text] [Related]
4. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.
Saland E; Boutzen H; Castellano R; Pouyet L; Griessinger E; Larrue C; de Toni F; Scotland S; David M; Danet-Desnoyers G; Vergez F; Barreira Y; Collette Y; Récher C; Sarry JE
Blood Cancer J; 2015 Mar; 5(3):e297. PubMed ID: 25794133
[TBL] [Abstract][Full Text] [Related]
5. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia.
Her Z; Yong KSM; Paramasivam K; Tan WWS; Chan XY; Tan SY; Liu M; Fan Y; Linn YC; Hui KM; Surana U; Chen Q
J Hematol Oncol; 2017 Oct; 10(1):162. PubMed ID: 28985760
[TBL] [Abstract][Full Text] [Related]
6. Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Sontakke P; Carretta M; Jaques J; Brouwers-Vos AZ; Lubbers-Aalders L; Yuan H; de Bruijn JD; Martens AC; Vellenga E; Groen RW; Schuringa JJ
Leukemia; 2016 Oct; 30(10):2064-2073. PubMed ID: 27125308
[TBL] [Abstract][Full Text] [Related]
7. [Establishment of a Patient-Derived T-Cell Acute Lymphoblastic Leukemia Xenograft Model in Novel Immunodeficient NCG Mice].
Jiang PJ; Dai XB; Kong XT; Xu ZQ; Yu H; Pang J; Xia W; Yu JH; Zhu GR; Tian F; Zhu XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):311-318. PubMed ID: 37096499
[TBL] [Abstract][Full Text] [Related]
8. The first Japanese biobank of patient-derived pediatric acute lymphoblastic leukemia xenograft models.
Tanaka K; Kato I; Dobashi Y; Imai JI; Mikami T; Kubota H; Ueno H; Ito M; Ogawa S; Nakahata T; Takita J; Toyoda H; Ogawa C; Adachi S; Watanabe S; Goto H
Cancer Sci; 2022 Nov; 113(11):3814-3825. PubMed ID: 35879192
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived intrafemoral orthotopic xenografts of peripheral blood or bone marrow from acute myeloid and acute lymphoblastic leukemia patients: clinical characterization, methodology, and validation.
Li J; Chen H; Zhao S; Wen D; Bi L
Clin Exp Med; 2023 Aug; 23(4):1293-1306. PubMed ID: 36121505
[TBL] [Abstract][Full Text] [Related]
10. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
Chen Y; Zhang R; Wang L; Correa AM; Pataer A; Xu Y; Zhang X; Ren C; Wu S; Meng QH; Fujimoto J; Jensen VB; Antonoff MB; Hofstetter WL; Mehran RJ; Pisimisis G; Rice DC; Sepesi B; Vaporciyan AA; Walsh GL; Swisher SG; Roth JA; Heymach JV; Fang B
Cancer; 2019 Nov; 125(21):3738-3748. PubMed ID: 31287557
[TBL] [Abstract][Full Text] [Related]
11. Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers.
Georgievski A; Bellaye PS; Tournier B; Choubley H; Pais de Barros JP; Herbst M; Béduneau A; Callier P; Collin B; Végran F; Ballerini P; Garrido C; Quéré R
Cell Death Dis; 2024 May; 15(5):328. PubMed ID: 38734740
[TBL] [Abstract][Full Text] [Related]
12. A robust xenotransplantation model for acute myeloid leukemia.
Sanchez PV; Perry RL; Sarry JE; Perl AE; Murphy K; Swider CR; Bagg A; Choi JK; Biegel JA; Danet-Desnoyers G; Carroll M
Leukemia; 2009 Nov; 23(11):2109-17. PubMed ID: 19626050
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Castillo-Ecija H; Pascual-Pasto G; Perez-Jaume S; Resa-Pares C; Vila-Ubach M; Monterrubio C; Jimenez-Cabaco A; Baulenas-Farres M; Muñoz-Aznar O; Salvador N; Cuadrado-Vilanova M; Olaciregui NG; Balaguer-Lluna L; Burgueño V; Vicario FJ; Manzanares A; Castañeda A; Santa-Maria V; Cruz O; Celis V; Morales La Madrid A; Garraus M; Gorostegui M; Vancells M; Carrasco R; Krauel L; Torner F; Suñol M; Lavarino C; Mora J; Carcaboso AM
J Pathol Clin Res; 2021 Jul; 7(4):338-349. PubMed ID: 33837665
[TBL] [Abstract][Full Text] [Related]
14. Human acute myeloid leukemia blast-derived exosomes in patient-derived xenograft mice mediate immune suppression.
Hong CS; Danet-Desnoyers G; Shan X; Sharma P; Whiteside TL; Boyiadzis M
Exp Hematol; 2019 Aug; 76():60-66.e2. PubMed ID: 31369790
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.
Wang K; Sanchez-Martin M; Wang X; Knapp KM; Koche R; Vu L; Nahas MK; He J; Hadler M; Stein EM; Tallman MS; Donahue AL; Frampton GM; Lipson D; Roels S; Stephens PJ; Sanford EM; Brennan T; Otto GA; Yelensky R; Miller VA; Kharas MG; Levine RL; Ferrando A; Armstrong SA; Krivtsov AV
Leukemia; 2017 Jan; 31(1):151-158. PubMed ID: 27363283
[TBL] [Abstract][Full Text] [Related]
16. Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.
Sivagnanalingam U; Balys M; Eberhardt A; Wang N; Myers JR; Ashton JM; Becker MW; Calvi LM; Mendler JH
PLoS One; 2015; 10(7):e0132375. PubMed ID: 26177509
[TBL] [Abstract][Full Text] [Related]
17. Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice.
Gopalakrishnapillai A; Kolb EA; Dhanan P; Bojja AS; Mason RW; Corao D; Barwe SP
Front Oncol; 2016; 6():162. PubMed ID: 27446808
[TBL] [Abstract][Full Text] [Related]
18. An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
Vick B; Rothenberg M; Sandhöfer N; Carlet M; Finkenzeller C; Krupka C; Grunert M; Trumpp A; Corbacioglu S; Ebinger M; André MC; Hiddemann W; Schneider S; Subklewe M; Metzeler KH; Spiekermann K; Jeremias I
PLoS One; 2015; 10(3):e0120925. PubMed ID: 25793878
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models.
Carretta M; de Boer B; Jaques J; Antonelli A; Horton SJ; Yuan H; de Bruijn JD; Groen RWJ; Vellenga E; Schuringa JJ
Exp Hematol; 2017 Jul; 51():36-46. PubMed ID: 28456746
[TBL] [Abstract][Full Text] [Related]
20. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
DeRyckere D; Lee-Sherick AB; Huey MG; Hill AA; Tyner JW; Jacobsen KM; Page LS; Kirkpatrick GG; Eryildiz F; Montgomery SA; Zhang W; Wang X; Frye SV; Earp HS; Graham DK
Clin Cancer Res; 2017 Mar; 23(6):1481-1492. PubMed ID: 27649555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
